secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001193125-23-042756
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica reports $34.3M cash; updates on VP-102 NDA and VP-315 Phase 2 trial
---------------------------------------------------------------------------

- Preliminary cash and cash equivalents of $34.3M as of Dec 31, 2022, unaudited and subject to change.
- NDA for VP-102 (molluscum contagiosum) resubmitted Jan 23, 2023; PDUFA goal date expected H2 2023.
- New CMO partner Piramal Pharma Solutions selected; technology transfer completed Jan 2023.
- VP-315 Phase 2 Part 1 (10 patients) showed favorable safety, no serious adverse events; Part 2 to start Q2 2023.
- Phase 3 trial for VP-102 (external genital warts) expected to initiate H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312523042756/0001193125-23-042756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312523042756/d467166d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-042756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer